A Randomized, Double-Blind, Placebo-Controlled, Mutilcenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Eevated Levels of C-Reactive Protein

Grants and Contracts Details

StatusFinished
Effective start/end date3/1/05 → 5/31/09

Funding

  • AstraZeneca Pharmaceuticals AB: $20,670.00